Curasight: The company raises capital to accelerate its therapeutic strategy
In their Q3 2023 report, Curasight announced their refocused strategic intention to further accelerate the integration and development of uTRACE and uTREAT – often referred to as the theranostic concept. At the accompanying event with HCA, CEO Ulrich Krasilnikoff and CSO Andreas Kjær explained their ambition to consider a future parallel development of uTRACE and uTREAT rather than the historical development of the two product which has been more sequential in nature. The idea is clearly to bring forward uTREAT since the product candidate for treatment of various cancer types is potentially the most valuable part of Curasight’s pipeline as CSO Andreas Kjær is citing analysts suggesting a value of uTREAT five to ten times bigger than the uTRACE candidate. While clear in their ambition, Curasight yesterday finally shed some lights on the practical execution of the idea as the company proposed a plan to do a Phase I/IIa so-called basket trial of uTRACE and uTREAT combined for five cancer indication adding the two new non-small cell lung and pancreatic cancer to the company’s well-known list of brain cancer, neuroendocrine tumors, and head-and-neck cancer indications.
Basket trial are FDA guided processes that intends to investigate more than one product candidate of various cancer types using the same master protocols. Curasight expects the first patients to be dosed in the beginning of 2025 and first efficacy data available later in 2025 and cites the new trials as the primary reason for the company’s intention to raise capital in a rights issue of DKK 51,2 million taking place from February 23rd to March 7th 2024. An Information Memorandum will be published on February 22nd and on February 27th you can participate in a HCA with CEO Ulrich Krasilnikoff and Andreas Kjær following the release of Curasight’s 2023 report and to learn more of Curasight’s ambition to accelerate its therapeutic strategy and hear details about the right issue.
To participate in the event, you can sign up here: Curasight event
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:35 AM 15-02-2024.
Curasight er en dansk biotekvirksomhed med fokus på at udvikle og forbedre opdagelsen og behandlingen af kræft på en mere skånsom og effektiv måde. På nuværende tidspunkt modtager patienter radioaktiv stråling i behandlingen mod kræft. Dette skader kræftcellerne, såvel som raske celler og væv i kroppen. Curasight teknologi er baseret på formålet om ikke at skade raske celler og væv. Virksomheden har to pipeline-produkter, der begge bruger radionuklid (nuklearmedicin) til at forbedre diagnosticering og behandling af forskellige kræfttyper; uTRACE bruger den såkaldte uPAR receptore som sidder på kræftceller, som en biomarkør til at diagnosticere kræften, samt dens udvikling. Selskabets andet product uTREAT, anvender uPAR som en receptor til at behandle kræften. Baseret på stærke fase 2-data, der allerede er indsamlet i 2022, forventes Curasight at forberede fase 3 til uTRACE senere i 2022 og 2023 for følgende fire kræfttyper: prostata, hjerne, neuroendokrine og hoved- og halskræft.
Read more on company page